Web3 jan. 2024 · Three mutations were located in the DNA-binding domain (two missense mutations, R162P and H163Y, and one frameshift early truncation mutation, D186fs, which lead to loss of DNA binding), while the other changes were distributed across the IKZF1 gene, particularly proximal to the C-terminal region. WebPresented at the 16 th Annual International Conference on Malignant Lymphoma: In June 2024, C4T presented pre-clinical data demonstrating CFT7455 binds to cereblon with …
IKZF1plus alterations are not associated with outcomes in …
Web1 jan. 2014 · Both IKZF1 and IKZF3 protein levels decrease markedly in primary human T cells treated with lenalidomide (Fig. 4D). Lenalidomide induced IL2 mRNA expression by … Web1 jan. 2014 · IKZF1 and IKZF3 are essential transcription factors in multiple myeloma. A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth. Similarly, we found that lenalidomide-induced IL2 production in T cells is due to depletion of IKZF1 and IKZF3. defeating bias
CELMoDs类IKZF 1/3 降解剂的研究进展
Web2 mei 2024 · (PDF) Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma Expression of CRBN, IKZF1, and... Web30 mrt. 2024 · In subgroup analysis, our results showed that IKZF1 mutation conferred poor therapeutic response and prognosis for SF3B1 -mutated AML (P = 0.0017). We believe … Web10 apr. 2024 · Although IKZF1 is elevated in malignant multiple myeloma for cancer cells survival and proliferation, IKZF1 protein acted as a tumor suppressor in different types of leukemia [13]. Notably, IKZF3 was also a transcription factor for the maturation of NK cells and the final differentiation of B cells, ... feedback incremental count error